Last reviewed · How we verify
Fluphenamic Acid (FLUFENAMIC ACID)
At a glance
| Generic name | FLUFENAMIC ACID |
|---|---|
| Drug class | flufenamic acid |
| Target | Nicotinate phosphoribosyltransferase |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Approved indications
- Pain
Common side effects
Key clinical trials
- Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks (PHASE1,PHASE2)
- Flufenamic Acid for Hospitalised Influenza Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluphenamic Acid CI brief — competitive landscape report
- Fluphenamic Acid updates RSS · CI watch RSS